FDA Rejects Stealth BioTherapeutics' Rare Disease Drug but Leaves Door Open for Accelerated Approval on May 29, 2025 3-Methylglutaconic aciduria type 2 Accelerated Approved Elamipretide Infrequent muscle strength endpoint Phase 2 trial rejection Stealth BioTherapeutics United States Food and Drug Administration +